Company Overview and News
2018-10-09 seekingalpha - 1
WallStars are distinguished by positive broker target price upsides. Industrial Metals, Chemicals, Coal, Steel, Lumber & Wood, and Paper topped October's Basic Materials WallStars for net gains calculated 10/5/18.
ARLP CCR TGLS GFI.WI SXCP DRD MLDUR FELP ANDA NBRXF DRDGF HCLP TGLSW GGB GSM BAK SWM EVA GFIOF SQM SID WPM OLN VHI CINR WLKP OSB KRO TX GFI ANDAW HPCO
2018-09-14 seekingalpha - 1
Sibanye-Stillwater has been hit hard by climbing AISC at its gold mines in South Africa, as well as worker deaths and a politically charged environment.
GFI.WI DRD MLDUR AAL JMPLF DRDGF SWC SBGL.WI AAUKF JMPLY GFI GFIOF NGLOY
2018-09-06 seekingalpha - 2
So thanks very much for joining us from -- and also for joining us at a slightly later hour to accommodate me because I'm dialing in from the United States. And hopefully, the results are good enough to make this worth your while to come in at this later hour. And I think the [indiscernible] will make up for it. So thanks for joining us early.
DRD MLDUR DRDGF
2018-08-01 fintel.io - 1
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
DRD AEZS MLDUR MS AEZ DRDGF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...